Royal DSM has been growing at a rate of 20 per cent and, with vitamin D deficiency on the increase in India, the company is scaling up its investments. “We have drawn up high growth plans for our Indian operations, with investments of $25-30 million planned in the near future,” says Rajiv Chopra, president, dsm India, and managing director, dsm Nutritional Products. “It will be even more, when the business grows.” The third, the China-based Zhejiang Garden Pharmaceutical Co Ltd, flourishes too and has assets of RMB12Q million.
“The dietary and neutraceutical supplements and food fortification segments have significant scope for enhancement in the global market,” adds Bains. “Fermenta is looking to enter these segments in a structured manner. It is also looking for experienced partners to tap the market.”
Fermenta is looking at exports of its vitamin D products in a big way, as there has been a steady growth in demand for its products. Today, its vitamin D exports constitute more than 65 per cent of its overall Vitamin D business. Its exports are spread over 35 countries. A significant portion of its sales comes from Europe, the US and Latin America (55 per cent of exports), with the Middle
East, Asia and China making up the rest (45 per cent).
To boost its global sales, Fermenta has tied up with DKSH, a Switzerland- based market expansion service provider, with a focus on Asia for the marketing and sales of the vitamin D3 product range for human and veterinary applications. The,partnership covers nine countries in South-East Asia – Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Sri Lanka, Taiwan, Thailand and Vietnam. Customers for vitamin D3 in each territory have been identified and DKSH’s local strength and experience in each territory is expected to help augment the sale of vitamin D3 in the South-east Asian market.
While FBI is focussing on growing its vitamin D portfolio, it will also continue to invest in developing
Strong R&D division
enzymes and technologies to replace the current chemical enzymatic processes. In the area of bio-enzymes, the company’s attention has been on the manufacture of semi-synthetic penicillin and its intermediates. While FBL traditionally used to manufacture the enzymes for the intermediates segment, which has witnessed a steady growth in demand, the launch of its new enzymes for making amoxicillin and ampicillin has also been received well. Almost all major manufacturers in India have adopted its new processes and enzymes. Even as the pressure to find environmen- tally-friendly processes is building up, the demand for solutions using bio-enzymes is also growing strong. So, FBL is investing in developing more such enzymes and technologies. About 50 per cent of its overall r&d spend is dedicated towards the
As a part of its expansion plans Fermenta has also entered Into the field of environmental solutions due to its expertise in the field of biotechnology. The company’s products and services in this segment reflect its core experience in handling enzymatic products, coupled with its collaboration with European partners, who have vast experience in these fields – such as treatment of waste water, as also water and soil contaminated with oil. Fermenta now offers environment solutions for sewage treatment, effluent treatment, municipal solid waste treatment, mud composting, oil sludge treatment and lake rejuvenation, with demand for such services mainly coming from engineering, procurement and construction companies, environmental consultants and municipal corporations,
On the front of waste water treatment, Fermenta has successfully worked with Nagpur Municipal Corporation. It is also treating waste water, using its product and services, in plants managed by Bellary and Tumkur Municipal Corporations, as well as treatment plants in Bangalore city, among others,
Impressed by FBI’s vast range of products and the increasing demand for vitamin D globally, Evolvence India Life Sciences Fund has acquired a 21 per cent stake in Fermenta for ?4Q crore. Fermenta has utilised this fund for the development of Its plant in Dahej,
Baines and Varma concur on the future of FBL and the vitamin D market. “Our aim is to make FBL the preferred supplier of vitamin D3 globally, offering all its variants,” they say. “Its formulation too is an important growth avenue for us and FBL has already initiated partnering with domestic marketing companies to strengthen their vitamin D3 formulation offerings. The company will soon be looking at a more holistic approach in tackling the pressing concerns of vitamin D3 deficiency through a consolidated effort, which includes awareness initiatives with key stakeholders,”
♦ ROBIN ABREU rQhin.abiemS’tjHslnessinclIflgroHp.com